{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-038108","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2024-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.596453+00:00","generated_at":"2026-05-31T01:48:49.354205+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"RenovoRx increases RenovoCath production, expands Medical Murray partnership with warrant for 709,500 shares","bullets":["RenovoRx boosts production of FDA-cleared RenovoCath catheter due to strong physician demand; over 500 procedures performed.","New work order with Medical Murray; RenovoRx issues warrant for up to 709,500 shares to incentivize manufacturing milestones.","Phase III TIGeR-PaC trial in pancreatic cancer continues; 52nd event (interim analysis) expected late 2024 or early 2025.","CEO expects commercial launch of RenovoCath as standalone device to generate revenue during 2025; sufficient cash on hand.","Robert Strasser promoted to VP of R&D and Operations to lead manufacturing and commercial strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-038108","json":"https://secwatch.observer/filing/0001493152-24-038108.json","markdown":"https://secwatch.observer/filing/0001493152-24-038108.md","text":"https://secwatch.observer/filing/0001493152-24-038108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224038108/0001493152-24-038108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224038108/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:48:49.354205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}